The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis

被引:30
作者
Ho, KM [1 ]
Lipman, J
Dobb, GJ
Webb, SAR
机构
[1] Royal Perth Hosp, Dept Intens Care, Perth, WA, Australia
[2] Univ Queensland, Royal Brisbane Hosp, Dept Intens Care Med, St Lucia, Qld 4067, Australia
[3] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia
关键词
D O I
10.1186/cc3883
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction High-risk surgical patients are at increased risk of fungal infections and candidaemia. Evidence from observational and small randomised controlled studies suggests that prophylactic fluconazole may be effective in reducing fungal infection and mortality. We evaluated the effects of prophylactic fluconazole on the incidence of candidaemia and hospital mortality in immunocompetent high-risk surgical patients. Methods Randomised controlled studies involving the use of fluconazole in immunocompetent high-risk surgical patients from the Cochrane Controlled Trial Register ( 2005, issue 1) and from the EMBASE and MEDLINE databases ( 1966 - 30 April 2005), without any language restriction, were included. Two reviewers reviewed the quality of the studies and performed data extraction independently. Results Seven randomised controlled studies with a total of 814 immunocompetent high-risk surgical patients were considered. The use of prophylactic fluconazole was associated with a reduction in the proportion of patients with candidaemia ( relative risk [RR] = 0.21, 95% confidence interval [CI] = 0.06 - 0.72, P = 0.01; I-2 = 0%) and fungal infections other than lower urinary tract infection ( RR = 0.39, 95% CI = 0.24 - 0.65, P = 0.0003; I-2 = 0%), but was associated with only a trend towards a reduction in hospital mortality ( RR = 0.82, 95% CI = 0.62 - 1.08, P = 0.15; I-2 = 7%). The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole ( RR = 0.35, 95% CI = 0.17 - 0.72, P = 0.004; I-2 = 0%). The proportion of patients colonised with or infected with fluconazole-resistant fungi was not significantly different between the fluconazole group and the placebo group ( RR = 0.66, 95% CI = 0.22 - 1.96, P = 0.46; I-2 = 0%). Conclusion The use of prophylactic fluconazole in immunocompetent high-risk surgical patients is associated with a reduced incidence of candidaemia but with only a trend towards a reduction in hospital mortality.
引用
收藏
页码:R710 / R717
页数:8
相关论文
共 38 条
[11]   Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients:: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination [J].
Garbino, J ;
Lew, DP ;
Romand, JA ;
Hugonnet, S ;
Auckenthaler, R ;
Pittet, D .
INTENSIVE CARE MEDICINE, 2002, 28 (12) :1708-1717
[12]   Impact of fluconazole administration on outcomes in critically ill patients [J].
Garrelts, JC ;
Schroeder, TR ;
Harrison, PB .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (10) :1588-1592
[13]   Candida infection of local necrosis in severe acute pancreatitis is associated with increased mortality [J].
Götzinger, P ;
Wamser, P ;
Barlan, M ;
Sautner, T ;
Jakesz, R ;
Függer, R .
SHOCK, 2000, 14 (03) :320-323
[14]  
He YM, 2003, WORLD J GASTROENTERO, V9, P2619
[15]   Measuring inconsistency in meta-analyses [J].
Higgins, JPT ;
Thompson, SG ;
Deeks, JJ ;
Altman, DG .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560
[16]   Fluconazole improves survival in septic shock: A randomized double-blind prospective study [J].
Jacobs, S ;
Evans, DAP ;
Tariq, M ;
Al Omar, NF .
CRITICAL CARE MEDICINE, 2003, 31 (07) :1938-1946
[17]   Fungal infections in critically ill patients - Rates are rising but diagnosis and treatment remain difficult [J].
Lipman, J ;
Saadia, R .
BRITISH MEDICAL JOURNAL, 1997, 315 (7103) :266-267
[18]   Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: Concepts and considerations [J].
Lipsett, PA .
CLINICAL INFECTIOUS DISEASES, 2004, 39 :S193-S199
[19]   Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients [J].
Magill, SS ;
Puthanakit, T ;
Swoboda, SM ;
Carson, KA ;
Salvatori, R ;
Lipsett, PA ;
Hendrix, CW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2471-2476
[20]   Issues in the design of the Fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantation [J].
Marr, KA .
CLINICAL INFECTIOUS DISEASES, 2004, 39 :S170-S175